Results of single and double autografts for high-risk neuroblastoma patients

被引:0
作者
KawaHa, K
YumuraYagi, K
Inoue, M
Park, DY
Okamura, T
Yasui, M
Oota, H
Sakata, N
Yoneda, M
Imura, K
机构
[1] OSAKA MED CTR,DEPT PEDIAT SURG,IZUMI,OSAKA 59002,JAPAN
[2] RES INST MATERNAL & CHILD HLTH,OSAKA,JAPAN
关键词
neuroblastoma; single autograft; double autograft;
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factors for relapse were the presence of bone lesions at diagnosis, and a minor response or progressive disease at transplantation. In order to improve the outcome of these high-risk patients, we tested the feasibility of double autografts. To date, eight patients have been treated, and no treatment-related deaths were observed. Six remain in CR or with stable disease for 6 to 29 months. Although more cases and longer observation are needed to draw conclusions, these results are encouraging.
引用
收藏
页码:957 / 962
页数:6
相关论文
共 26 条
[1]   TREATMENT OF ADVANCED NEURO-BLASTOMA WITH SUPRALETHAL CHEMOTHERAPY, RADIATION, AND ALLOGENEIC OR AUTOLOGOUS MARROW RECONSTITUTION [J].
AUGUST, CS ;
SEROTA, FT ;
KOCH, PA ;
BURKEY, E ;
SCHLESINGER, H ;
ELKINS, WL ;
EVANS, AE ;
DANGIO, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (06) :609-616
[2]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[3]   MYELOABLATIVE THERAPY AND UNPURGED AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR POOR-PROGNOSIS NEUROBLASTOMA - REPORT OF 34 CASES [J].
DINI, G ;
LANINO, E ;
GARAVENTA, A ;
ROGERS, D ;
DALLORSO, S ;
VISCOLI, C ;
CASTAGNOLA, E ;
MANNO, G ;
BRISIGOTTI, M ;
ROSANDA, C ;
PASINO, M ;
RIVABELLA, L ;
BONI, L ;
MARCHESE, N ;
IVANI, G ;
RIZZO, A ;
FRANZONE, P ;
TRASINO, S ;
DEBERNARDI, B .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) :962-969
[4]  
DINI G, 1989, BONE MARROW TRANSPL, V4, P42
[5]  
EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO
[6]  
2-G
[7]   BONE-MARROW TRANSPLANTATION FOR HIGH-RISK NEUROBLASTOMA AT THE CHILDRENS-HOSPITAL-OF-PHILADELPHIA - AN UPDATE [J].
EVANS, AE ;
AUGUST, CS ;
KAMANI, N ;
BUNIN, N ;
GOLDWEIN, J ;
ROSS, AJ ;
DANGIO, GJ .
MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 23 (04) :323-327
[8]  
GRAEVE JLA, 1988, CANCER, V62, P2125, DOI 10.1002/1097-0142(19881115)62:10<2125::AID-CNCR2820621010>3.0.CO
[9]  
2-1
[10]  
GRAHAMPOLE J, 1991, J CLIN ONCOL, V9, P152